Skip to content

Efficacy of Yuvnam Shaurya Oil on reducing Erectile Dysfunction

Post-marketing open label observational clinical study w.r.t local application of Yuvnam Shaurya Oil in Erectile Dysfunction

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045961
Enrollment
60
Registered
2022-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N529- Male erectile dysfunction, unspecified

Interventions

None listed

Sponsors

YUVNAM PRIVATE LIMITED
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male 18 years and above experiencing functional ED, which will be defined as the inability to achieve or maintain erection for satisfactory sexual intercourse for more than 3 months duration. 2.All patients experiencing a 50% or greater failure rate to maintain an erection on at least 4 separate attempts over the 4-week treatment-free baseline period. 3.The decision for â??functionalâ?? character of ED will be taken based on the following: a.Good nocturnal erection prior to 2 weeks b.One event of sexual intercourse prior to 2 weeks c.Good erection during masturbation or visual sex stimulation 4.Patients willing to give written informed consent. 5.Patients are fit and no need for any hospital administration. 6.Agree to following instruction of doâ??s and donâ??ts in regular daily lifestyle. 7.Patients willing to perform all study related procedures including the use of study medicine, allow the physical and other tests and willing to document symptoms and medication.

Exclusion criteria

Exclusion criteria: 1.Conditions that preclude study entry included anatomical abnormalities of the penis, radical prostatectomy, spinal cord injury, unstable angina pectoris and myocardial infarction. 2.Patients will be also excluded if they had hypertension or poorly controlled diabetes mellitus with complications. 3.Patients receiving hormonal treatment, treatment with antidepressants, antipsychotic or other psychoactive drugs, or those with serene psychiatric symptoms will also be excluded. 4.Inability to carry out visits for the study. 5.Chronic & acute disorders requiring hospital admission 6.Known HIV-positive, Hepatitis B or C status. 7.Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.

Design outcomes

Primary

MeasureTime frame
1.Frequency of erection during sexual activity. 2.Quality of erection during sexual activity. 3.Maintenance of erection till the end of intercourse. 4.Confidence in getting and keeping erection. International Index of Erectile Functioning (IIEF) The Erection Hardness Score (EHS) Timepoint: 4 weeks

Secondary

MeasureTime frame
No incidence of Adverse events (AE) and Serious Adverse Events (SAE) during the study periodTimepoint: 4 weeks

Countries

India

Contacts

Public ContactDR JAYESH THAKKAR

The Ayurveda Clinic and Research Centre

docdebnath84@gmail.com9836675720

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026